MARKET

NKTR

NKTR

Nektar Therapeutics
NASDAQ
44.00
-1.43
-3.15%
Pre Market: 44.75 +0.75 +1.70% 08:52 12/19 EST
OPEN
45.57
PREV CLOSE
45.43
HIGH
46.89
LOW
42.62
VOLUME
311
TURNOVER
0
52 WEEK HIGH
66.92
52 WEEK LOW
6.48
MARKET CAP
895.03M
P/E (TTM)
-5.5510
1D
5D
1M
3M
1Y
5Y
1D
Nektar Therapeutics: Alopecia Update And A Look At The Road Ahead For Rezpeg
Seeking Alpha · 1d ago
Jefferies Sticks to Its Buy Rating for Nektar Therapeutics (NKTR)
TipRanks · 2d ago
Promising Data from REZOLVE-AA Trial Positions REZPEG as a Safer, Effective Treatment for Alopecia Areata with Undervalued Stock
TipRanks · 2d ago
Promising Efficacy and Safety of Rezpegaldesleukin Positions Nektar Therapeutics as a Leader in Alopecia Areata Treatment
TipRanks · 2d ago
Nektar Therapeutics Price Target Raised to $118.00/Share From $100.00 by BTIG
Dow Jones · 2d ago
Nektar Therapeutics Is Maintained at Buy by BTIG
Dow Jones · 2d ago
Pliant Therapeutics Appoints Minnie Kuo as Chief Operating Officer
Reuters · 2d ago
Cautious Hold Rating for Nektar Therapeutics Amid Mixed Rezpeg Trial Results
TipRanks · 2d ago
More
About NKTR
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.

Webull offers Nektar Therapeutics stock information, including NASDAQ: NKTR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NKTR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NKTR stock methods without spending real money on the virtual paper trading platform.